DK1737485T3 - Vaccine med mucinøst glycoprotein (muc-1) - Google Patents

Vaccine med mucinøst glycoprotein (muc-1)

Info

Publication number
DK1737485T3
DK1737485T3 DK05769609.8T DK05769609T DK1737485T3 DK 1737485 T3 DK1737485 T3 DK 1737485T3 DK 05769609 T DK05769609 T DK 05769609T DK 1737485 T3 DK1737485 T3 DK 1737485T3
Authority
DK
Denmark
Prior art keywords
muc
vaccine
mucinous glycoprotein
mucinous
glycoprotein
Prior art date
Application number
DK05769609.8T
Other languages
English (en)
Inventor
B Michael Longenecker
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Application granted granted Critical
Publication of DK1737485T3 publication Critical patent/DK1737485T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05769609.8T 2004-04-01 2005-04-01 Vaccine med mucinøst glycoprotein (muc-1) DK1737485T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55813904P 2004-04-01 2004-04-01
US57680404P 2004-06-04 2004-06-04
PCT/IB2005/002479 WO2005112546A2 (en) 2004-04-01 2005-04-01 Mucinous glycoprotein (muc-1) vaccine

Publications (1)

Publication Number Publication Date
DK1737485T3 true DK1737485T3 (da) 2014-08-04

Family

ID=35428714

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11196228.8T DK2524700T3 (da) 2004-04-01 2005-04-01 Mucinøst glykoprotein (muc-1) -vaccine til behandlingen af prostatakræft
DK05769609.8T DK1737485T3 (da) 2004-04-01 2005-04-01 Vaccine med mucinøst glycoprotein (muc-1)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11196228.8T DK2524700T3 (da) 2004-04-01 2005-04-01 Mucinøst glykoprotein (muc-1) -vaccine til behandlingen af prostatakræft

Country Status (16)

Country Link
US (2) US9173929B2 (da)
EP (2) EP1737485B1 (da)
JP (3) JP5590768B2 (da)
CN (2) CN1997388B (da)
AR (1) AR051350A1 (da)
AU (1) AU2005244675B2 (da)
BR (1) BRPI0509552A (da)
CA (1) CA2562990A1 (da)
DK (2) DK2524700T3 (da)
ES (2) ES2478006T3 (da)
HK (1) HK1109574A1 (da)
HU (1) HUE027378T2 (da)
PL (2) PL2524700T3 (da)
PT (2) PT2524700E (da)
TW (2) TW201204410A (da)
WO (1) WO2005112546A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
AU2012268892B2 (en) * 2005-06-28 2016-05-26 Oncothyreon Inc. Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine
ES2526344T3 (es) 2005-06-28 2015-01-09 Oncothyreon Inc. Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1)
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
KR101452033B1 (ko) * 2008-12-17 2014-10-21 온코타이레온, 인코포레이티드 소형 리포솜의 제조 방법
WO2011054359A2 (en) * 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
JP5978204B2 (ja) 2010-04-19 2016-08-24 住友ベークライト株式会社 癌関連糖ペプチドエピトープ、抗体および使用方法
CN103781469B (zh) 2011-02-24 2015-09-16 肿瘤防护公司 含有佐剂的以muc1为基础的糖脂肽疫苗
KR102425466B1 (ko) 2011-06-24 2022-07-25 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법
DE102011085695A1 (de) * 2011-11-03 2013-05-08 Jörg Pohl Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
JP2016520073A (ja) 2013-05-14 2016-07-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｍｕｃ−１リポペプチドによるワクチン免疫で肺癌を治療する方法
CA2915904A1 (en) * 2013-08-21 2015-02-26 Curevac Ag Composition and vaccine for treating prostate cancer
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
CN110393797A (zh) * 2019-05-27 2019-11-01 南开大学 基于糖脂佐剂的糖肽疫苗的制备方法与应用
US11878057B2 (en) * 2020-12-11 2024-01-23 Trustees Of Boston University Immunomodulatory lipopolysaccharide compositions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) * 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
ATE72123T1 (de) 1985-04-19 1992-02-15 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
US5837249A (en) * 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) * 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
DK0478715T3 (da) 1989-06-23 1996-08-05 Liposome Co Inc Målrettede liposomer og fremgangsmåder til liposom-protein-kobling
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5993823A (en) * 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
US5871746A (en) * 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en) * 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1996040236A1 (en) 1995-06-07 1996-12-19 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecules and uses thereof
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
CA2249395A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
AU2284697A (en) 1996-04-11 1997-10-29 University Of British Columbia, The Fusogenic liposomes
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
DE69842060D1 (de) 1997-05-08 2011-01-27 Oncothyreon Inc Verfahren zur Gewinnung aktivierter T-Zellen und mit Antigen-inkubierten Antigen-präsentierender Zellen
JPH11139961A (ja) 1997-11-06 1999-05-25 Taisho Pharmaceut Co Ltd リポソームの製造方法
JP2002509102A (ja) 1998-01-16 2002-03-26 バイオミラ・ユーエスエイ・インコーポレイテッド リポマトリックス製剤
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US6104536A (en) 1998-09-18 2000-08-15 3M Innovative Properties Company High efficiency polarization converter including input and output lenslet arrays
JP2002529240A (ja) * 1998-11-13 2002-09-10 オプタイム セラピュウティクス， インコーポレイテッド リポソーム生成のための方法および装置
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
AU778701B2 (en) 1999-09-08 2004-12-16 Imperial Cancer Research Technology Ltd MUC-1 derived peptides
WO2001036433A2 (en) 1999-11-15 2001-05-25 Biomira, Inc. Synthetic lipid-a analogs and uses thereof
US20020018806A1 (en) * 2000-03-24 2002-02-14 Babita Agrawal Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
EP1203614A1 (de) * 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
JP2004522717A (ja) * 2000-12-01 2004-07-29 バイオミラ，インコーポレイテッド Ｐｅｇへの注入による大型リポソームの作製
ES2424131T3 (es) * 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
EP1458242A4 (en) * 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
JP3760467B2 (ja) * 2002-04-09 2006-03-29 ソニー株式会社 コンテンツ再生装置および方法、記録媒体、並びにプログラム
EP1572918B1 (en) 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
ATE457733T1 (de) 2002-05-09 2010-03-15 Oncothyreon Inc Lipid-a- und andere kohlenhydrat-liganden-analoga
US20030235610A1 (en) 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
WO2004071638A2 (en) 2003-02-11 2004-08-26 Regents Of The University Of California, The Microfluidic devices and method for controlled viscous shearing and formation of amphiphilic vesicles
US9198645B2 (en) * 2003-11-26 2015-12-01 The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology Controlled vesicle self-assembly in continuous two phase flow microfluidic channels
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
ES2526344T3 (es) 2005-06-28 2015-01-09 Oncothyreon Inc. Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1)
CA2616877C (en) 2005-07-27 2014-01-28 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
JP5126874B2 (ja) 2007-05-21 2013-01-23 国立大学法人神戸大学 リポソーム製剤の製造方法
KR101452033B1 (ko) * 2008-12-17 2014-10-21 온코타이레온, 인코포레이티드 소형 리포솜의 제조 방법

Also Published As

Publication number Publication date
JP5868125B2 (ja) 2016-02-24
PL1737485T3 (pl) 2014-10-31
HK1109574A1 (en) 2008-06-13
TW200538147A (en) 2005-12-01
HUE027378T2 (en) 2016-10-28
CN1997388B (zh) 2014-03-26
EP1737485A2 (en) 2007-01-03
WO2005112546A3 (en) 2006-05-04
CN1997388A (zh) 2007-07-11
AU2005244675B2 (en) 2011-07-21
PL2524700T3 (pl) 2016-04-29
PT2524700E (pt) 2016-02-29
EP2524700A1 (en) 2012-11-21
CA2562990A1 (en) 2005-12-01
JP2012092105A (ja) 2012-05-17
US20160082093A1 (en) 2016-03-24
TWI395591B (zh) 2013-05-11
US9173929B2 (en) 2015-11-03
AU2005244675A1 (en) 2005-12-01
BRPI0509552A (pt) 2007-09-18
EP1737485A4 (en) 2008-09-03
WO2005112546A2 (en) 2005-12-01
EP2524700B1 (en) 2015-10-28
PT1737485E (pt) 2014-08-22
US20080131495A1 (en) 2008-06-05
JP5590768B2 (ja) 2014-09-17
JP2014177479A (ja) 2014-09-25
ES2560808T3 (es) 2016-02-22
DK2524700T3 (da) 2016-02-01
EP1737485B1 (en) 2014-05-07
TW201204410A (en) 2012-02-01
CN103933556A (zh) 2014-07-23
AR051350A1 (es) 2007-01-10
JP2007530663A (ja) 2007-11-01
ES2478006T3 (es) 2014-07-18

Similar Documents

Publication Publication Date Title
DK1737485T3 (da) Vaccine med mucinøst glycoprotein (muc-1)
MA28609B1 (fr) Vaccins
MA28639B1 (fr) Vaccins
DK2047779T3 (da) Kaffemaskine
DK2462972T3 (da) Nasal indgivelsesindretning
DE602005027159D1 (de) Kopfstütze
MA28885B1 (fr) vaccins
DE602005023954D1 (de) Hubsystem
DE602005017454D1 (de) Siliziumverbindung
FI20041690A0 (fi) Hissijärjestelmä
FR2878515B3 (fr) Tire-bouchon
DK1711188T3 (da) Anticancerterapier
AT500095B1 (de) Transdermales abgabesystem
DK1815144T3 (da) Skovlhjul
IS2922B (is) Bóluefni
DK1720633T3 (da) Skrubber
AT7801U3 (de) Ausgabeaufsatz
DK1600416T3 (da) Løftesystem
FI20040796A0 (fi) Hissijärjestelmä
DE602005017643D1 (de) Medikamentenverdunster
DE602004031265D1 (de) Aufzugsvorrichtung
FI20040936A0 (fi) Imulaite
NL1028040A1 (nl) Gebogen athermische pseudokinematische standaard.
DE502005004299D1 (de) Liefergerät
DE112005003066A5 (de) Geodätisches Gerät